Key result
Coagulation and plasminogen pathway abnormalities drive prostate cancer progression and highlight potential antiangiogenic targets.
Patients with prostate carcinoma paradoxically have both a hypercoagulable state and a bleeding diathesis. Hypercoagulability manifested by venous and arterial thrombosis has been documented in several large clinical trials. However, many investigators have reported a high risk of postoperative bleeding in prostate cancer patients. Disseminated intravascular coagulopathy has also been commonly noted at different clinical stages of this indolent cancer. In this article we review clinical, laboratory, and experimental evidence for abnormalities of various components of the coagulation and plasminogen pathways and analyze their contribution in prostate cancer growth, progression, and angiogenesis. Finally, we propose potential therapeutic antiangiogenic strategies in patients with prostate cancer.
No takes yet. Share an insight, caveat, or question.
Kohli et al. (2003) conducted a review in Prostate cancer. Coagulation and fibrinolytic system abnormalities was evaluated. Abnormalities of coagulation and plasminogen pathways contribute to prostate cancer growth, progression, and angiogenesis, providing potential targets for therapeutic antiangiogenic strategies.
Synapse has enriched 5 related papers. Consider them for comparative context: